This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nakata, K. Articles by Nakamura, S. Search for Related Content PubMed PubMed Citation Articles by Nakata, K. Articles by Nakamura, S.

Augmented Antitumor Effect of Recombinant Human Interleukin-1 by Indomethacin

Research Laboratories, Dainippon Pharmaceutical Co., Ltd., Enoki-cho 33-94, Suita, Osaka 564, Japan

In murine syngeneic tumor models, the antitumor effect of recombinant human interleukin-1 (rHu IL-1) was significantly augmented by oral coadministration of indomethacin (IND). The augmentation was more or less observed by various routes of rHu IL-1 (i.m., i.v., and intratumoral routes), against various tumors (Meth A sarcoma, colon 26 adenocarcinoma, B16 melanoma, and Lewis lung carcinoma) and irrespective of administration timings (in early and late stages of tumor growth). This result suggests that prostaglandin E₂ produced by host cells in response to rHu IL-1 and/or by tumor mass might interfere with the antitumor activity of rHu IL-1 and also that cyclooxygenase inhibitors such as IND might counteract such interference. In the combination of rHu IL-1 with IND, its efficacious doses (5–50 µg/kg) against murine tumors were at least 300–3000 times lower than its median lethal dose (more than 15 mg/kg). In addition, IND partially prevented the loss of body weight attributed to rHu IL-1 injections at relatively high doses. Combined use of rHu IL-1 with IND seems to be desirable from both therapeutic and toxicological viewpoints.

¹ To whom requests for reprints should be addressed.

Received 7/ 1/87. Revised 10/16/87. Accepted 10/26/87.

This article has been cited by other articles:

				A. Martin-Ancel, A. Garcia-Alix, D. Pascual-Salcedo, F. Cabanas, M. Valcarce, and J. Quero Interleukin-6 in the Cerebrospinal Fluid After Perinatal Asphyxia Is Related to Early and Late Neurological Manifestations Pediatrics, November 1, 1997; 100(5): 789 - 794. [Abstract] [Full Text] [PDF]